Pharmaceuticals

GRANDPHARMA

Yttrium-90 Microspheres Clinical Trial for Inoperable Hepatocellular Carcinoma Reaches Endpoint

Farasis and HKU Form Strategic Partnership to Advance Innovative Antibacterial Drug Development

Farmito Pharmaceutical's Registered Capital Increased to About 3.43 Billion RMB

GRANDPHARMA released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 3.088 B, actual EPS HKD 0.0102

GRANDPHARMA released FY2025 9 Months Earnings on March 26 (BJT), actual revenue HKD 9.195 B, actual EPS HKD 0.344

Yuanda Pharmaceutical Reports FY2025 Financials Revealing Revenue, Profits, and Innovation Progress

GRANDPHARMA released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 12.28 B (forecast HKD 12.18 B), actual EPS HKD 0.3543 (forecast HKD 0.61)

GRANDPHARMA released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 3.088 B, actual EPS HKD 0.0102

Furadai Pharmaceutical Secures NMPA Approval for II-Phase Clinical Study of GPN01020 for Migraine

GRANDPHARMA to Release FY2025 Earnings on March 26 During-Market (BJT), Forecast Revenue HKD 12.18 B, EPS HKD 0.61

Furay Medicine Submits New Drug Application for TLX591-CDx to China's NMPA

Huadaxiyao's Radiopharmaceutical TLX250-CDx Clinical Trial Results Published

Farmiton Medical Multiple Innovative Products Show Promising Clinical Progress

Farasis Medical Acquires Hebei Yunda Jiufu Biotechnology Co., Ltd. to Strengthen Amino Acid Industrial Chain Layout

Yuanda Pharmaceutical Makes Breakthroughs in Nuclear Medicine Oncology

Farapulse Secures Commercialization Rights for Neffy® in Mainland China

Farmito Obtains Exclusive Commercialization Rights for Neffy® in Mainland China

Yongan Pharmaceutical's TLX591-CDx Phase III Clinical Trial Reaches Primary Endpoint

Fujian Grand Pharmaceutical's Radioactive Drug Approved by FDA for Clinical Trials

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.06.12, Cash dividend 0.169 HKD

00512

Grand Pharmaceutical Group (SEHK:512) reported positive results from its DOORwaY90 trial for liver cancer treatment, meeting clinical endpoints. Despite recent share price declines of 5.35% over 30 days and 16.69% over 90 days, the company shows long-term shareholder returns of 11.04% and 54.32% over one and three years, respectively. Currently trading at HK$6.54, the stock has a P/E ratio of 18.5x, below the peer average of 29.6x, suggesting potential value. However, risks remain regarding R&D execution and recent price weakness. A DCF model values the stock at HK$8.65, indicating a 24% discount.

Simplywall

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After Positive DOORwaY90 Liver Cancer Trial Results

513700

159992

513060

510660

516500

520880

520690

159506

000963

159316

516930

513120

Grand Pharmaceutical Group (SEHK:512) has received China approval for eye treatment GPN01768 and advanced migraine drug GPN01020 to Phase II trials. The stock trades at HK$7.22, with a 6.49% return over the past week but a 7.44% decline over 90 days. The P/E ratio of 20.4x suggests good value compared to its fair P/E of 25.1x and peer average of 21.6x, despite risks from clinical trials and revenue concentration. A DCF model estimates a future cash flow value of HK$22.44 per share, indicating a significant valuation gap.

Penghua CSI HK Connect Health Care Composite ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

HUADONG MEDICINE

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

GRAND HOLDING

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC CSI All Share Health Care Devices ETF

Assessing Grand Pharmaceutical Group (SEHK:512) Valuation After China Drug Approvals And Earnings Update

捍宇医疗

520500

Grand Pharmaceutical Group's shares rose 9.7% following its mixed 2025 results, which showed increased sales of HK$12,283.27 million but a significant drop in net income and EPS. The company announced a lower annual dividend and highlighted challenges from centralized drug procurement. However, it received approval for new drugs, GPN01768 and GPN01020, aimed at treating Demodex blepharitis and migraines, respectively. Investors are weighing the potential of these innovations against current profit pressures and margin compression.

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Why Grand Pharmaceutical Group (SEHK:512) Is Up 9.7% After Mixed 2025 Results And New Drug Milestones

Grand Pharmaceutical Group (SEHK:512) reported its 2025 results with increased sales but lower net income and a reduced dividend. The share price is HK$6.78, reflecting a 3.04% daily return and a 12.52% return over 30 days. The P/E ratio stands at 19.1x, suggesting it may be undervalued compared to its fair value of HK$22.44 per share according to DCF analysis. However, risks include recent share price weakness and profit pressure. Investors are encouraged to evaluate the mixed signals regarding growth and income potential.

A Look At Grand Pharmaceutical Group (SEHK:512) Valuation After 2025 Earnings Reset And New Ophthalmic Drug Approval

GRANDPHARMA announced its 2025 annual performance, with revenue of 12.283 billion yuan, an increase of 5.5% year-on-year; gross profit of 6.78 billion yuan, a slight increase of 0.6%. It recorded a net profit of 1.241 billion yuan, a decline of 49.7%, with earnings per share of 35.44 cents. The final dividend is 16.9 Hong Kong cents, compared to 26 Hong Kong cents in the same period last year

AASTOCKS

"Performance" GRANDPHARMA's annual net profit is 1.241 billion yuan, a decrease of 49.7%, with a final dividend of 16.9 cents

CS精准医

Belief BioMed and Grand Life Sciences have announced an exclusive partnership to commercialize BBM-H803, a gene therapy for hemophilia A, in China, Hong Kong, Macau, and Taiwan. This collaboration aims to leverage both companies' strengths to accelerate the commercialization process and improve patient access to innovative treatments. The agreement was signed by key executives from both companies, highlighting their commitment to addressing the unmet clinical needs of hemophilia A patients. BBM-H803 is an AAV-based gene therapy designed to enhance coagulation factor levels in patients, with ongoing trials and regulatory approvals in place.

prnewswire

China Merchants CSI Biotechnology Theme ETF

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

01:48 ETBelief BioMed and Grand Life Sciences Announced Exclusive Commercial Partnership in the Field of Hemophilia A, Bringing Innovative Gene Therapy to Chinese Patients

GRANDPHARMA(00512.HK)